Azafaros will host a satellite symposium entitled "The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience" on February 3 at 17:45 PT, ...
Scientific posters will be displayed in the Experience Hub on Thursday, July 16 with the Welcome Reception. Presenters are expected to be present with their poster to discuss their research and ...
Upon abstract acceptance, all posters must be uploaded and recorded on VoiceThread by January 26, 2026 at 5 p.m. All posters that are narrated on VoiceThread by the deadline will be officially listed ...
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs ...
Posters are a staple of scientific communication, and most trainees will make at least one poster during their time in graduate school. However, despite posters being the second-most popular means of ...
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in ...
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results